INI 822
Alternative Names: INI-822Latest Information Update: 13 Aug 2024
Price :
$50 *
At a glance
- Originator Inipharm
- Class Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action HSD17B13 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 05 Jun 2024 Pharmacokinetics data from a phase I in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress, 2024 (EASL-2024)
- 05 Jun 2024 Pharmacokinetics data from a preclinical studies in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress, 2024 (EASL-2024)
- 22 May 2024 Efficacy data from a phase I trial in Non-alcoholic steatohepatitis released by Inipharm